about
Tamoxifen and breast cancer risk in women harboring a BRCA1 germline mutation: computed efficacy, effectiveness and impact.[Syncope and lipothymia of carotid sinus origin. Apropos of 13 cases of carotid sinus syndrome of the cardio-inhibitory form].Impact of organised programs on colorectal cancer screening.Attitudes towards cancer predictive testing and transmission of information to the familyMedical counselling in the clinical management of BRCA mutation.Clinical utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) - update 2012.Cancer screening in France: subjects' and physicians' attitudes[Automatic non-ambulatory measurement of arterial pressure. Computer data-analysis of the evaluation of antihypertensive treatment]Prophylactic mastectomy: ethical issues.Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study.Cancer screening: reaching the limits or terra incognita? Lessons from the EDIFICE surveys.Links between personality, time perspective, and intention to practice physical activity during cancer treatment: an exploratory study.ARLTS1, potential candidate gene in familial aggregation of hematological malignancies.Impact of general practitioners' sex and age on systematic recommendation for cancer screening.Maintaining professional activity during breast cancer treatment.Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis.Genetic testing for familial cancer. The French National Report (year 2003).Social stratification, risk factor prevalence and cancer screening attendance.Prostate cancer screening: contrasting trends.[Self-employed and small business owners diagnosed with cancer: effect on entrepreneurial survival].Lung cancer risks, beliefs and healthcare access among the underprivileged.Breast cancer screening controversy: too much or not enough?Cancer screening in France: third edition of the EDIFICE survey.Typical medullary breast carcinomas have a basal/myoepithelial phenotype.Cigarette smoking in women after BRCA1/2 genetic test disclosure: a 5-year follow-up study of the GENEPSO PS cohort.Phenocopies: actual risk or self-fulfilling prophecy?Organized colorectal cancer screening programmes: how to optimize efficiency among general practitioners.Re: Performance of first mammography examination in women younger than 40 years.Tamoxifen's effect in women with breast cancer.PS2 expression in BRCA1-associated breast cancers.An alternative to prophylactic colectomy for colon cancer prevention in HNPCC syndrome.Increasing coverage rates for mammographic screening in France in older women--16 years of follow-up.Cancer survivors: familial risk perception and management advice given to their relatives.Screening for prostate cancer: growth without control.Molecular study of CEBPA in familial hematological malignancies.GATA2 gene analysis in several forms of hematological malignancies including familial aggregations.Mutational analysis of JAK2, CBL, RUNX1, and NPM1 genes in familial aggregation of hematological malignancies.Familial hematological malignancies: new IDH2 mutation.CYP2D6 and Ockham's razor.Cultural basis for differences between US and French clinical recommendations for women at increased risk of breast and ovarian cancer.
P50
Q31685836-3C2E0F6E-D190-4271-8F78-2B32CE1D4131Q33173244-000C5DFC-DD43-49A2-A454-7439A76EF3ABQ33328300-E479FDB6-2C7E-4DC9-A999-FE53F92B9EC3Q33677753-B16D9A2A-03EC-4010-B2E1-FCC51D5D435AQ35065752-76A45A67-4E51-469E-9676-CC26D64C60E6Q36497317-D334EBAC-F172-4FE8-B1E1-EE8782EBD837Q36570120-42122223-5016-44D0-8F99-C861FA68F6CBQ36631252-9FC5A98A-084D-47E5-93B4-4A1ABD231690Q36780409-E8FF0465-5BFB-4626-B171-B8AA39F02952Q37694797-956E9887-4970-4920-9C42-C68DE4427130Q37829851-BA0C1C81-A32A-490B-8FB7-885BD1089FC0Q38852317-CB431113-ABE4-4293-9A21-99BAF7EFAC80Q39042557-186655A5-AC0C-4DD8-94F7-EFFB22531BF8Q39967060-7C049889-ADF3-455E-8B80-EC8BBA58587EQ39986728-9EFA2EA6-571A-442A-AF30-753119526D6BQ40035188-2D6284CD-186B-4304-91B4-05596746B53BQ40134059-A1CE30F5-803B-4331-91B4-858341B981A8Q40897749-C36D5CC2-D719-474E-9AD6-082B1C51DC57Q41140930-FFC4D498-3B9A-48E9-824F-33AC094EE31CQ41591944-A73C84E4-3BDC-429D-B439-E8EF1F370A71Q41714118-1378C118-56D2-48EA-A3B8-712997D8104FQ41714130-2107CC73-11C3-4433-98BD-1DDB24A7BB67Q41714137-19C129B1-7362-488C-B86C-57A54A7A2134Q42484066-BC64891B-1A0F-471E-B6B6-FA7C07299699Q42699298-0E6B307B-58B3-4C81-BEE6-9304995A1FB9Q43232457-98CA8E00-ABF1-4A9D-8A7E-78DB7C90DD0AQ43498724-23F537C0-5A6F-4EBC-81BF-2E2DC4315200Q43612853-D6443BF2-D25F-42C0-BBBA-221099EF0BA6Q43649688-AA356B37-DD5A-43B1-B242-166C944BFD0FQ43802058-7D664558-C43D-48B7-8D54-EE289FEDCD80Q43875595-304E7F66-1528-4D91-AFEF-3175EDCCDB6DQ43997187-8AECB45F-3A0B-4EAD-97B0-547AB8A6053FQ44601918-13A25392-AF0D-40D4-BD20-FABADA915EA6Q45086803-65AAC2AA-55BA-4379-BA2A-03A67B463432Q46006129-69216B9A-648A-442B-971B-110A66EA3107Q46394161-4ACF235E-E11E-462C-B6D8-42B8464150C8Q46616674-6F8D2317-F442-43C7-AB6A-ABA2ED337DB2Q46677889-20D255BC-1793-4D3A-B445-FD5A88D3858FQ46781988-58F3D6FC-6AC2-4FD8-88E7-82370CF1B73FQ47724109-4E5D6FEC-D8C2-4368-9843-449AC4E5F5A7
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
F Eisinger
@ast
F Eisinger
@en
F Eisinger
@es
F Eisinger
@nl
F Eisinger
@sl
type
label
F Eisinger
@ast
F Eisinger
@en
F Eisinger
@es
F Eisinger
@nl
F Eisinger
@sl
prefLabel
F Eisinger
@ast
F Eisinger
@en
F Eisinger
@es
F Eisinger
@nl
F Eisinger
@sl
P106
P1153
7102354995
P31
P496
0000-0002-8794-0681